Peponen (Capsules) Instructions for Use
Marketing Authorization Holder
Teva Pharmaceutical Industries, Ltd. (Israel)
Manufactured By
Teva Pharmaceutical Works, Private Limited Company (Hungary)
ATC Code
G04CX (Other preparations for the treatment of benign prostatic hyperplasia)
Active Substance
Pumpkin seed (BP British Pharmacopoeia)
Dosage Form
| Peponen | Capsules 300 mg: 90 or 100 pcs. |
Dosage Form, Packaging, and Composition
Capsules soft gelatin, reddish-brown in color.
| 1 caps. | |
| Pumpkin seed oil | 300 mg |
10 pcs. – blisters (10) – cardboard packs.
10 pcs. – blisters (9) – cardboard packs.
Clinical-Pharmacological Group
Herbal preparation used for functional urinary disorders associated with benign prostatic hyperplasia
Pharmacotherapeutic Group
Herbal remedy for the treatment of prostate adenoma
Pharmacological Action
An agent of plant origin. It contains biologically active substances obtained from pumpkin (carotenoids, tocopherols, phospholipids, sterols, phosphatides, flavonoids, vitamins B1, B2, C, P, PP, F, saturated, unsaturated and polyunsaturated fatty acids – palmitic, stearic, oleic, linoleic, linolenic, arachidonic). It has antiulcer, hepatoprotective and choleretic effects. Reduces the proliferation of prostate cells. It has an anti-inflammatory effect.
Pumpkin seeds have anthelmintic activity against tapeworms (including beef tapeworm, pork tapeworm, dwarf tapeworm, broad tapeworm). It is believed that the component with anthelmintic action is contained mainly in the thin gray-green shell inside the pumpkin seed.
Indications
For oral administration: hepatitis, fatty liver dystrophy, cholecystocholangitis, biliary dyskinesia, gastritis, heartburn, gastric and duodenal ulcer, colitis, enterocolitis, hemorrhoids, atherosclerosis, prostatitis, benign prostatic hyperplasia, cervical erosion. Deworming and prevention of parasite carriage of various tapeworms.
For external and local use: herpes, dermatitis, diathesis, psoriasis, eczema, burns and burn disease, periodontitis.
ICD codes
| ICD-10 code | Indication |
| B00 | Herpesviral [herpes simplex] infections |
| B83.9 | Helminthiases, unspecified |
| I70 | Atherosclerosis |
| K05 | Gingivitis and periodontal diseases |
| K25 | Gastric ulcer |
| K26 | Duodenal ulcer |
| K29 | Gastritis and duodenitis |
| K52.9 | Noninfective gastroenteritis and colitis, unspecified |
| K64 | Hemorrhoids and perianal venous thrombosis |
| K73 | Chronic hepatitis, not elsewhere classified |
| K76.0 | Fatty (change of) liver, not elsewhere classified |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K82.8 | Other specified diseases of gallbladder and cystic duct (including dyskinesia) |
| K83.0 | Cholangitis |
| L20.8 | Other atopic dermatitis (neurodermatitis, eczema) |
| L30.0 | Nummular eczema |
| L30.9 | Dermatitis, unspecified |
| L40 | Psoriasis |
| N40 | Hyperplasia of prostate |
| N41 | Inflammatory diseases of prostate |
| N86 | Erosion and ectropion of cervix |
| R12 | Heartburn |
| T30 | Burns and corrosions of unspecified body region |
| ICD-11 code | Indication |
| 1F00.Z | Infections due to herpes simplex virus, unspecified |
| 1F9Z | Helminthiases, unspecified |
| 9A06.70 | Atopic eczema of the eyelids |
| BD40.Z | Atherosclerosis of peripheral arteries, unspecified |
| DA0B.Z | Gingival diseases, unspecified |
| DA0C.Z | Periodontal diseases, unspecified |
| DA0Z | Diseases or disorders of the orofacial complex, unspecified |
| DA42.Z | Gastritis, unspecified |
| DA51.Z | Duodenitis, unspecified |
| DA60.Z | Gastric ulcer, unspecified |
| DA63.Z | Duodenal ulcer, unspecified |
| DA7Z | Diseases of stomach or duodenum, unspecified |
| DA90.0 | Syndromic diarrhea |
| DB6Z | Hemorrhoids or perianal venous diseases, unspecified |
| DB92.0 | Non-alcoholic fatty liver disease without steatohepatitis |
| DB92.Y | Other specified non-alcoholic fatty liver disease |
| DB92.Z | Non-alcoholic fatty liver disease, unspecified |
| DB97.2 | Chronic hepatitis, not elsewhere classified |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC13 | Cholangitis |
| DC1Z | Diseases of gallbladder and biliary tract, unspecified |
| DD94 | Functional disorder of the gallbladder |
| DE2Z | Diseases of the digestive system, unspecified |
| EA80.0 | Infantile atopic eczema |
| EA80.1 | Childhood atopic eczema |
| EA80.2 | Adult atopic eczema |
| EA80.Z | Atopic eczema, unspecified |
| EA82 | Nummular dermatitis |
| EA85.20 | Atopic hand eczema |
| EA85.2Z | Hand dermatitis, unspecified |
| EA85.3 | Foot dermatitis |
| EA89 | Generalized eczematous dermatitis of unspecified type |
| EA8Z | Dermatitis or eczema, unspecified |
| EA90.Z | Psoriasis, unspecified |
| GA15.1 | Erosion or ectropion of cervix |
| GA90 | Hyperplasia of prostate |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| MD95 | Heartburn |
| NE11 | Burn of unspecified body region |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Take orally with a sufficient amount of water.
For benign prostatic hyperplasia and prostatitis, take 300 mg three times daily.
For gastritis, gastric ulcer, duodenal ulcer, and heartburn, take 300 mg two to three times daily.
For hepatitis, fatty liver dystrophy, cholecystocholangitis, and biliary dyskinesia, take 300 mg three times daily.
For colitis and enterocolitis, take 300 mg twice daily.
For hemorrhoids, take 300 mg twice daily for a minimum of two weeks.
For atherosclerosis, take 300 mg three times daily for a prolonged duration.
For cervical erosion, take 300 mg twice daily.
For deworming of tapeworms, take a single dose of 5 grams to 10 grams for adults, or 150 mg/kg to 200 mg/kg for children, on an empty stomach.
For external use in herpes, dermatitis, psoriasis, eczema, and burns, apply the oil contents of the capsule topically to the affected area two to three times daily.
For periodontitis, apply the oil topically to the gums.
The duration of treatment is determined by the physician based on the clinical indication and patient response.
Adverse Reactions
When taken orally, mild belching is possible, rarely – diarrhea.
Contraindications
Not established.
Pediatric Use
Use is possible according to the dosage regimen.
Special Precautions
Can be used as monotherapy and as part of combination therapy.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer